Cultivates and produces medical cannabis products in-house. Distributes cannabis products through Trulieve-branded dispensaries. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.9× for every dollar of annual revenue.
Analysts' average target sits 292% above today's price.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $1.2B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $118.4M against $1.2B in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 21 sells against just 1 buy. Not an alarm bell by itself, but a number worth watching.
Against everything we grade, TCNNF lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: TCNNF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
Not covered, because the filings we hold do not carry it: the revenue breakdown.